IPP Bureau

Emmes appoints Matt Bond as CFO
Emmes appoints Matt Bond as CFO

By IPP Bureau - October 05, 2023

His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy

Alembic received 6 USFDA approvals during Q2FY24
Alembic received 6 USFDA approvals during Q2FY24

By IPP Bureau - October 05, 2023

The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets

Strides receives USFDA approval for Icosapent Ethyl capsules
Strides receives USFDA approval for Icosapent Ethyl capsules

By IPP Bureau - October 04, 2023

The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin

Lupin launches patient support program ‘Humrahi‘  for diabetes management
Lupin launches patient support program ‘Humrahi‘ for diabetes management

By IPP Bureau - October 04, 2023

India has the highest prevalence of diabetes globally, with an estimated 77 million people living with the condition and an expected 134 million cases by 2045

Aurobindo Pharma completes sale of Antibiotic business to Apitoria Pharma
Aurobindo Pharma completes sale of Antibiotic business to Apitoria Pharma

By IPP Bureau - October 03, 2023

The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete

AstraZeneca Pharma India gets permission to import Palivizumab solution for injection
AstraZeneca Pharma India gets permission to import Palivizumab solution for injection

By IPP Bureau - October 03, 2023

Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus

Zydus announces IND clearance of a novel Anti-PCSK9 candidate
Zydus announces IND clearance of a novel Anti-PCSK9 candidate

By IPP Bureau - October 03, 2023

Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity

Nobel prize 2023 for medicine awarded to Katalin Karikó, Drew Weissman for research on mRNA vaccines to fight Covid-19
Nobel prize 2023 for medicine awarded to Katalin Karikó, Drew Weissman for research on mRNA vaccines to fight Covid-19

By IPP Bureau - October 03, 2023

The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19

Briefs: Aurobindo Pharma and Balaxi Pharmaceuticals
Briefs: Aurobindo Pharma and Balaxi Pharmaceuticals

By IPP Bureau - October 03, 2023

Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company

Solvay celebrates Medicine Nobel Prize winner Katalin Karikó
Solvay celebrates Medicine Nobel Prize winner Katalin Karikó

By IPP Bureau - October 03, 2023

Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate

SigTuple’s AI100 with Shonit receives USFDA 510(k) clearance
SigTuple’s AI100 with Shonit receives USFDA 510(k) clearance

By IPP Bureau - October 03, 2023

SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology

Solvay launches new PVDC coating solution for more sustainable pharma blister films
Solvay launches new PVDC coating solution for more sustainable pharma blister films

By IPP Bureau - October 03, 2023

Diofan Ultra736 provides ultra-high water vapor barrier with excellent thermoformability, unlocking the potential to design thinner and more sustainable blister films

Advent International announces the completion of the acquision of Suven Pharma
Advent International announces the completion of the acquision of Suven Pharma

By IPP Bureau - September 30, 2023

New Board of Directors and management team at Suven Pharma also appointed

Menarini strengthens its presence in aesthetic dermatology in India
Menarini strengthens its presence in aesthetic dermatology in India

By IPP Bureau - September 30, 2023

The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation

Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 manufacturing facility
Lupin Receives EIR from U.S. FDA for its Nagpur Unit-1 manufacturing facility

By IPP Bureau - September 30, 2023

The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated

Latest Stories

Interviews

Packaging